KatherineNWeilbaecherMD
Oncology • Saint Louis, MOAssociate Professor, Internal Medicine, Washington University School of Medicine
Dr. Weilbaecher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
7th Floor Suite A
Saint Louis, MO 63110Phone+1 314-362-5677Fax+1 314-362-7086- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1993 - Present
MO State Medical License 2000 - 2025
MA State Medical License 1994 - 2001- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients Start of enrollment: 2006 Jan 01
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.Liao, M., Webster, J., Coonrod, E., Maher, C., White, N., Weilbaecher, K.> ;Clinical Breast Cancer. 2024 Feb 16
- 9 citationsGenomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.Andrew A Davis, Jingqin Luo, Tiantian Zheng, Chao Dai, Xiaoxi Dong, Lu Tan, Rama Suresh, Foluso O Ademuyiwa, Caron Rigden, Timothy P Rearden, Katherine Clifton, Kather...> ;Clinical Cancer Research. 2023 May 1
- 2 citationsA phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN).Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo,...> ;NPJ Breast Cancer. 2023 Jan 6
- Join now to see all
Journal Articles
- Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone LossKatherine Weilbaecher, MD, Clinical Cancer Research
- The β3‐Integrin Endothelial Adhesome Regulates Microtubule‐Dependent Cell MigrationKatherine Weilbaecher, MD, Molecular Systems Biology
Press Mentions
Capitol Dome to Be Lit Pink to Honor Breast Cancer PatientsOctober 18th, 2018
Grant Support
- Next Generation Approaches To Breast Cancer Using Image Guided Drug DeliveryNational Cancer Institute2011–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2003–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2009
- Microphthalmia In Osteoclast DevelopmentNational Institute On Aging2000–2002
Professional Memberships
- Member
Hospital Affiliations
Barnes-Jewish HospitalSaint Louis, Missouri
Siteman Cancer CenterSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
